Contraria Biotech utilizes a cutting-edge technology platform centered around modified Outer Membrane Vesicles (mOMVs) to develop innovative vaccines and immunotherapeutics. This versatile platform leverages bacteria to produce self-adjuvanting vesicles that can effectively deliver antigenic molecules. The mOMV technology is particularly advantageous for large-scale, cost-effective production, demonstrating high immunogenicity and good tolerability in human trials. The company is focused on addressing the pressing global health challenge of antimicrobial resistance (AMR) by developing vaccines against Gram-negative bacteria, which pose significant threats due to their increasing resistance to existing antibiotics.

In addition to mOMVs, Contraria Biotech is pioneering a "Lab 4.0" approach to vaccine development, which integrates intelligent networks of equipment and open data systems to enhance the efficiency and control of biopharmaceutical processes in real-time. This innovative model aims to streamline the early-stage development of new biopharmaceutical products, particularly those involving recombinant proteins. By combining advanced clinical-immunology-guided reverse vaccinology with the flexibility of the mOMV platform, Contraria Biotech is working towards creating effective vaccines against various infectious diseases, including meningococcal disease and gonorrhea, while also exploring solutions for malaria and other significant health threats.

Italy

Contraria Biotech (formerly AchilleS Vaccines) is a biopharmaceutical development company that aims to create sustainable therapeutic and prophylactic drugs against infectious diseases. We are committed to designing innovative, cost-effective therapeutic and prophylactic products to address some of today's major global health problems, including antibiotic resistance, emerging diseases and pandemics.

Contraria Biotech

Company Details